233 Results for "

deficient

" in MedChemExpress (MCE) Product Catalog:
Products (233)

233 Results for "deficient" in MCE Product Catalog:

49
49 Publications Verification
Cat. No.: HY-10626
CAS No.: 293754-55-9
Purity:  99.93%
T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-101903
CAS No.: 300657-03-8
Purity:  99.93%
Target:  

FABP

BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-101903A
CAS No.: 2802523-05-1
Purity:  99.93%
Target:  

FABP

BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-14622
CAS No.: 852391-19-6
Purity:  99.92%
Target:  

RIP kinase

Research Areas:  

Cancer

Necrostatin 2 is a potent necroptosis inhibitor. EC50 for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114778
CAS No.: 1358715-18-0
Purity:  99.96%
Synonyms: SHR3162; Fuzuloparib
Target:  

PARP

Research Areas:  

Cancer

Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC50=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-A0143
CAS No.: 1783-84-2
Synonyms: DGLA; all-cis-8,11,14-Eicosatrienoic acid
Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-A0143A
CAS No.: 65881-87-0
Synonyms: DGLA sodium; all-cis-8,11,14-Eicosatrienoic acid sodium
Dihomo-γ-linolenic acid (DGLA; all-cis-8,11,14-Eicosatrienoic acid) sodium is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid (sodium) attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-149004
CAS No.: 2763730-97-6
Purity:  98.02%
Target:  

LPL Receptor

Research Areas:  

Inflammation/Immunology

SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC50=1.93 μM). SLF1081851 plays a key role in development and immune system .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-124691
CAS No.: 688342-78-1
Purity:  99.70%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-12689
CAS No.: 1260075-17-9
Purity:  99.84%
Synonyms: AG-348
Target:  

Pyruvate Kinase

Research Areas:  

Metabolic Disease

Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0327
CAS No.: 57381-26-7
Synonyms: Dicloguamine
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer [5][6] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-153367
CAS No.: 2676211-64-4
Purity:  99.15%
FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD, Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100746
CAS No.: 315702-99-9
Purity:  98.69%
Target:  

Autophagy

Research Areas:  

Cancer

STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC50 of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively) .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W011552R
CAS No.: 2140-79-6
2'-O-Methyladenosine (Standard) is the analytical standard of 2'-O-Methyladenosine. This product is intended for research and analytical applications. 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W012926
CAS No.: 504-07-4
Synonyms: 5,6-Dihydrouracil
Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148764
CAS No.: 890808-56-7
Purity:  99.90%
Research Areas:  

Cancer

M47 is a molecular glue that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W017540
CAS No.: 35404-50-3
Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145925B
CAS No.: 2704617-96-7
Purity:  98.10%
Research Areas:  

Cancer

CFT8634 is an orally active BRD9 PROTAC degrader with a DC50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-159989
CAS No.: 3118919-69-7
Research Areas:  

Cancer

UNC10142 (Compound 44) is a first-in-class small molecule antagonist of CHD1 that binds with an IC50 value of 1.7 μM. UNC10142 leads to a dose-dependent reduction in viability in PTEN-deficient prostate cancer cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N7501
CAS No.: 486-63-5
Isoformononetin is an analog of Daidzein (HY-N0019) and has immunoprotective effects. Isoformononetin inhibits the differentiation of Th17 and B-cells lymphopoesis to promote osteogenesis in estrogen-deficient bone loss conditions .
loading...
    loading...